GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sernova Corp (XTER:PSH) » Definitions » Debt-to-EBITDA

Sernova (XTER:PSH) Debt-to-EBITDA : -0.02 (As of Jan. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Sernova Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sernova's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$0.09 Mil. Sernova's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$0.55 Mil. Sernova's annualized EBITDA for the quarter that ended in Jan. 2024 was C$-38.51 Mil. Sernova's annualized Debt-to-EBITDA for the quarter that ended in Jan. 2024 was -0.02.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Sernova's Debt-to-EBITDA or its related term are showing as below:

XTER:PSH' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.14   Med: -0.04   Max: 0
Current: -0.02

XTER:PSH's Debt-to-EBITDA is ranked worse than
100% of 278 companies
in the Biotechnology industry
Industry Median: 1.375 vs XTER:PSH: -0.02

Sernova Debt-to-EBITDA Historical Data

The historical data trend for Sernova's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sernova Debt-to-EBITDA Chart

Sernova Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.14 -0.06 -0.01 -

Sernova Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 - - -0.02

Competitive Comparison of Sernova's Debt-to-EBITDA

For the Biotechnology subindustry, Sernova's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sernova's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sernova's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Sernova's Debt-to-EBITDA falls into.



Sernova Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sernova's Debt-to-EBITDA for the fiscal year that ended in Oct. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.136 + 0) / -38.52
=-0.00

Sernova's annualized Debt-to-EBITDA for the quarter that ended in Jan. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.088 + 0.546) / -38.512
=-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jan. 2024) EBITDA data.


Sernova  (XTER:PSH) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Sernova Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Sernova's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Sernova (XTER:PSH) Business Description

Traded in Other Exchanges
Address
700 Collip Circle, The Stiller Centre, Suite 114, London, ON, CAN, N6G 4X8
Sernova Corp is a clinical-stage company developing products for the treatment of chronic debilitating diseases. The company is engaged in the research and development of its proprietary Cell Pouch and associated technologies including immune-protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and or hormones for the long-term treatment of multiple serious, chronic diseases such as diabetes, hemophilia, and thyroid disease.

Sernova (XTER:PSH) Headlines